UroGen Pharma Ltd. 4

Chief Medical Officer Mark Schoenberg sold 10,000 UroGen Pharma (URGN) ordinary shares at about $40 per share under a Rule 10b5-1 plan.

On July 9, 2026, UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares of URGN at a weighted average price of approximately $40.00 per share, for total proceeds of about $400,000, in a transaction executed under a pre-established Rule 10b5-1 trading plan that has now completed its final sale. Following this disposition, Schoenberg’s direct ownership stands at 119,763 ordinary shares. The sale was executed in multiple trades between $40.00 and $40.02 per share, and the insider has committed to provide detailed trade breakdowns upon request to the issuer, its security holders, or the SEC staff.

Filing Facts

CIK

1668243

Ticker

URGN

Form

4

Source Type

fda

Accession

0001437749-26-023290

Alert Tier

6